Adaptimmune to ‘redefine’ itself as a sarcoma biotech, cuts a third of staffersnews2024-11-15T11:56:34+00:00November 15th, 2024|Endpoints News|
New Zealand clears first clinical trial of epigenetic editing for hepatitis Bnews2024-11-14T16:12:43+00:00November 14th, 2024|Endpoints News|
GSK’s Blenrep combo meets key survival endpoint in Phase 3 multiple myeloma testnews2024-11-14T11:04:54+00:00November 14th, 2024|Endpoints News|
Danish biotech Gubra touts early weight loss data in hot amylin fieldnews2024-11-13T19:27:48+00:00November 13th, 2024|Endpoints News|
Adaptimmune’s second T cell receptor cell therapy for rare sarcomas passes pivotal testnews2024-11-13T16:07:00+00:00November 13th, 2024|Endpoints News|
After stock slides, Amgen addresses bone density talk on obesity drugnews2024-11-13T12:20:55+00:00November 13th, 2024|Endpoints News|
Syros’ shares plummet as blood cancer drug fails againnews2024-11-13T11:29:54+00:00November 13th, 2024|Endpoints News|
Syndax’s menin inhibitor succeeds in pivotal trial, but investors aren’t impressednews2024-11-12T20:29:16+00:00November 12th, 2024|Endpoints News|
Merck, AstraZeneca tout Phase 3 win for Koselugo in neurofibromatosisnews2024-11-12T19:48:28+00:00November 12th, 2024|Endpoints News|
Merck KGaA plans China submission after late-stage win for tumor drugnews2024-11-12T16:09:12+00:00November 12th, 2024|Endpoints News|
